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Background: Quantitative measurements in the myocardium may be used to detect both focal and diffuse disease
processes that result in an elevation of T1 and/or extracellular volume (ECV) fraction. Detection of abnormal
myocardial tissue by these methods is affected by both the accuracy and precision. The sensitivity for detecting
abnormal elevation of T1 and ECV is limited by the precision of T1 estimates which is a function of the number and
timing of measurements along the T1-inversion recovery curve, the signal-to-noise ratio (SNR), the tissue T1, and
the method of fitting.
Methods: The standard deviation (SD) of T1 and ECV estimates are formulated and SD maps are calculated on a
pixel-wise basis using the Modified Look-Locker Inversion recovery (MOLLI) method. SD estimates are validated by
numerical simulation using Monte-Carlo analysis and with phantoms using repeated trials. SD estimates are
provided for pre- and post-contrast optimized protocols for a range of T1s and SNRs. In-vivo examples are provide
for normal, myocarditis, and HCM in human subjects. The formulation of SD maps was extended to R1 and ECV.
Results: The measured myocardial SNR ranged from 23 to 43 across the heart using the specific T1-mapping
protocol in this study. In this range of SNRs, the estimated SD for T1 was approximately 20-45 ms for pre-contrast
myocardial T1 around 1000 ms, and was approximately 10-20 ms for post contrast T1 around 400 ms. The proposed
estimate of SD was an unbiased estimate of the standard deviation of T1 validated by numerical simulation and
had > 99% correlation with phantom measurements. The measured SD maps exhibited variation across the heart
due to drop off in surface coil sensitivity as expected for the variation in SNR. Focal elevation in T1 and ECV was
shown to have statistical significance on a pixel-wise basis for in-vivo examples.
Conclusions: Pixel-wise estimates of T1 mapping errors have been formulated and validated, and the
formulation has been extended to ECV. The ability to quantify the measurement error has potential to determine
the statistical significance of subtle abnormalities that arise due to diffuse disease processes involving fibrosis
and/or edema and is useful both as a confidence metric for overall quality, and in optimization and comparison
of imaging protocols.
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Quantitative methods such as T1-mapping and extra-
cellular volume (ECV) mapping appear promising to
complement LGE imaging in cases of more homoge-
neously diffuse disease which affect the myocardial
extracellular space [1-17]. Quantitative measurements
in the myocardium may be used to detect both focal
and diffuse disease processes that result in an eleva-
tion of T1 and/or ECV.
Direct measurement of extracellular volume (ECV) was
initially developed for quantifying the myocardial extra-
cellular fractional distribution volume [1] and has been
proposed as a means for detection and quantification of
diffuse myocardial fibrosis [2-6,15-17]. This approach is
based on the change in T1 following administration of an
extracellular contrast agent and circumvents the limitation
of LGE in detecting a global change in T1, which typically
uses a single post-contrast T1 measurement. The myocar-
dial ECV is measured as the percent of tissue comprised
of extracellular space, which is a physiologically intuitive
unit of measurement. ECV has been shown to correlate
with collagen volume fraction [3,5]. The topic of ECV
mapping as well as native T1-mapping is of current inter-
est as a diagnostic tool for a wide range of cardiomyopa-
thies including dilated cardiomyopathy [2], diffuse fibrosis
associated with myocardial dysfunction in congenital heart
disease [4], aortic stenosis and HCM [5], cardiac amyloid-
osis [15], Anderson Fabry [17], myocardial infarction
[8,11], as well as aging processes [8].
The sensitivity for detecting abnormal elevation of T1
and ECV is limited by the precision of T1 estimates
which is a function of the number and timing of mea-
surements along the T1-inversion recovery curve, the
signal-to-noise ratio (SNR), the tissue T1, and the
method of fitting. Detection of abnormal myocardial
tissue by these methods is affected by both the accuracy
and precision. In this work, we only consider the ran-
dom component due to noise which limits precision and
not bias errors that affects accuracy. Although absolute
accuracy of in-vivo measurements is an important and
open subject, these methods have been shown to be
highly reproducible [18] in practice despite bias errors.
Quantifying the statistical fluctuation of measured T1
could improve confidence in assessing the significance
of results. We propose to produce a map calibrated in
T1 units that represents the quality of the T1 estimate,
by transforming the standard deviation (SD) of residual
fitting error into the SD of the estimated parameters.
The estimate of the T1 parameter error based on the fit
residuals is derived analytically, and validated on phan-
tom measurements. Robust methods for both fitting and
estimating the SD of the underlying measurements are
described. In-vivo examples are shown to demonstrate
the potential utility.Methods
Theory
The sensitivity for detecting abnormal elevation of T1 is
limited by the precision of T1 estimates, which in the
case of inversion recovery methods is a function of the
number and timing of measurements along the T1-
recovery curve, the signal-to-noise ratio, tissue T1,
method of fitting, and the accuracy of the model. Physio-
logic fluctuation is not considered. It is proposed to pro-
duce a standard deviation (SD) map calibrated in T1
units that represented the standard deviation of the T1
estimate, by transforming the SD of the residual fitting
error into the SD of the estimated parameters. Estimate
of the T1 parameter error based on fit residuals is
derived analytically, and validated by both Monte-Carlo
numerical simulation and phantom measurements using
repeated trials.
Inversion recovery is widely used for T1-mapping
using Look-Locker methods. In applications such as
cardiac MR, a modified Look-Locker (MOLLI) method
[9,10] uses inversion recovery with multiple single shot
images at different inversion times. Pixel-wise paramet-
ric mapping is accomplished by performing a curve fit to
the multiple inversion time measurements. The original
MOLLI paper [9] assumes a 3-parameter model of the
form S(ti) = A – B exp(-ti/T1*), where T1* < T1 repre-
sents the apparent T1 which is shortened by the influ-
ence of imaging RF pulses. The desired T1 is then
calculated at each pixel using T1 = T1*·(B/A-1), referred
to as the Look-Locker correction, originally derived from
considering a continuous fast low angle shot (FLASH)
gradient echo readout [19]. The Look-Locker correction
is used in MOLLI despite the fact that imaging uses
non-continuous balanced steady-state free precession
(bSSFP), which violates the assumption used in the
formulation. This assumption is a key source of bias
error not treated in this paper and is sensitive to vari-
ables such as T1 and T2 as described in the literature
[9,20,21]. In this work, we only consider the random
component due to noise which limits precision and not
bias errors that affect accuracy (Figure 1).
A phase sensitive (PSIR) reconstruction was used [22]
to restore the sign and thereby avoid performing a
magnitude fit, or performing multiple fits to estimate
the zero crossing [9]. In PSIR reconstruction, the real
component is used which results in normally distributed
noise [23]. The 3-parameter model may be written as:
y tð Þ ¼ A−B ⋅ exp − t
T1
 




and the measurements y(t) may be fit for the unknown
parameters (A, B, T1) at each pixel using a downhill sim-
plex minimization approach (Nelder–Mead method) [24].
Figure 1 Illustration of accuracy versus precision.
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parameters (A, B, T1) may be approximated as [25]:
C ¼ inv D1=2









where the matrix D1/2 is a first order approximation to
the Hessian matrix D. D is comprised of second order

























































after having dropped the second order terms in D. D1/2
is comprised of the partial derivatives of the signal
Eq (1) relative to the estimated parameters, derived ana-
lytically for each inversion time ti as:
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The noise of the PSIR reconstructed measurements is
normally distributed with standard deviation σi for each
measurement which can be treated as equal acrossmeasurements (σi = σ) and are estimated at each pixel
from the fit residuals. Although the measurements are
very well approximated as normal, the parameter esti-
mates themselves may not be normally distributed due
to the non-linearity of the model. However, in our ex-
perience the parameter estimates (A, B, and T1) were
well approximated as normal in the range of SNR
encountered.
The above formulation may also be extended to ECV
maps, where ECV is calculated as:








In this case, it is assumed that the random noise com-
ponent in the ECV measurement is dominated by the
myocardium since the R1 in the blood is measured in a
large ROI, which reduces the noise. The calculation of
SD is reformulated for R1 = 1/T1 by substituting δy/δR1
for δy/δT1 in Eq (3) above.
∂y
∂R1
¼ t⋅ B=A−1ð Þ⋅B ⋅ exp −t⋅ B=A−1ð Þ⋅R1ð Þ ð6Þ
The SD for ECV is calculated as:







which is dominated by the post-contrast variation,
i.e. σR1post., due to the increased value of R1 following
administration of contrast.
Robust estimation
Robust estimation was used for both fitting for T1 as
well as for estimation of the standard deviation, σ, of the
measurements. Robust fitting [26,27] uses iterative re-
weighting to improve the fit in the presence of outliers.
At each iteration, the weighting of outliers is reduced
based on the value of their residuals. For instance, out-
liers may result from errors such as residual uncorrected
motion. Additionally, a robust estimation of the under-
lying standard deviation (σ) from the fit residuals is used
based on the median absolute deviation (MAD) ap-
proach [26,28]. The MAD estimate σ is calculated from
the residuals εi = (fit – meas) as:
σ ¼ median abs rið Þð Þ=0:6745 ð8Þ
where ri are the residuals εi after discarding the (p-1)
values with lowest magnitude, p = 3 is the number of pa-
rameters being fit, and the scale factor 0.6745 is used for
noise which is normally distributed. The scale factor
is calculated as the median of the absolute value
of normally distributed noise with standard deviation
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to avoid a bias error due to over fitting.
The estimated SD for the corresponding T1-map value
is calculated at each pixel producing a SD map, follow-
ing the flow chart in Figure 2.Numerical validation
A Monte-Carlo simulation using N = 65,536 trials was
used to compute the standard deviation in T1 (σT1) as a
function of SNR, and T1 for a specific MOLLI protocol
(5-3 sampling, TImin = 105 ms, TI shift = 80 ms) and
T2 = 45 ms, and was compared with the estimate of
standard deviation based on the proposed approach
using the fit residuals. Each trial used independent noise
with a normal distribution. In order to test the robust-
ness to outliers, a separate test was conducted which
compared the robust iteratively re-weighted and stand-
ard methods in the presence of outliers. For this com-
parison, a single outlier with a randomly positioned
inversion time (i.e., 1 of the 8 measurements) had a
noise standard deviation corresponding to 6 times the
noise standard deviation of the other measurements.
In addition to measuring the accuracy of the esti-
mate of SD, i.e. whether the estimate is unbiased, the
variability or standard deviation of the standard devi-
ation estimate was measured.Figure 2 Pixel-wise calculation of SD values based on fit residuals.Phantom validation
Experimental validation was performed using phantoms
by repeated measurements (n = 200 repetitions) of a set
of T1-measurements comparing estimated and calcu-
lated standard deviations. A “measured” SD was calcu-
lated for each pixel, and compared with the mean of the
estimated SD map values for the corresponding pixel.
Phantom validation used a set of CuSO4 doped agar gel
phantoms with varying concentrations with T1 and T2
in the expected range for myocardium, both native and
with Gd contrast. Phantoms had T1 in the range
250-1600 ms and T2 in the range 40-75 ms.Imaging
Imaging was performed on 32 channel 1.5 T Siemens
Avanto and Espree scanners (Siemens Medical Solutions,
Erlangen, Germany), equipped with 45 mT/m and
200 T/m/s, and 33 mT/m and 170 T/m/s gradient sys-
tems, respectively. The MOLLI imaging protocol used in
this study acquired data with 2 protocols (sampling
strategies). The first protocol was optimized for native
(pre-contrast) myocardial T1 values and the second
protocol was optimized for shorter T1 corresponding to
Gd contrast. The MOLLI imaging protocol used for
native T1 acquired data at 8 inversion times over an 11
heart beat breath-hold at end-expiration with 2 inversions.
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protocol used a 5(3)3 scheme, acquiring 5 images after
the first inversion, a 3 second pause for recovery, and
3 images acquired after the second inversion. The
protocol used with Gd contrast had a 4(1)3(1)2 sam-
pling scheme which acquired 9 images in 11 heart-
beats with 3 inversions which was found to improve
the T1 estimate. For the contrast protocol with shor-
ter T1, a shorter recovery period (1s) is used between
inversions, which permits additional samples of the in-
version recovery at short inversion times in the same
overall breath-hold duration.
Typical imaging parameters for both sampling schemes
were: non-selective adiabatic inversion pulse, steady state
free precession single shot read out with 35° excitation flip
angle, typical field of view 360 × 270 mm2, slice thickness
6 mm, minimum inversion time 110 ms, inversion time
increment 80 ms, 7/8 partial Fourier plus parallel imaging
factor 2. A 2.56 ms tan/tanh adiabatic inversion pulse
was used to improve the inversion efficiency at the
low values of myocardial T2. For heart rates below
90 bpm we typically used: matrix 256 × 144, voxel size
1.4 × 1.9 × 6.0 mm3, TR/TE 2.7/1.1 ms, with 200 ms
readout imaging duration. For heart rates above
90 bpm a matrix of 192 × 130 was used.Figure 3 Measured (dots) vs calculated (circles) standard deviation of
strategies, 5(3)3 and 4(1)3(1)2, from Monte-Carlo simulation with 65,5
(right column).Images were reconstructed using a phase sensitive
method which incorporates non-rigid correction of
respiratory motion [22]. Co-registration between pre-
and post-contrast acquired image series was performed
in the generation of ECV maps [13]. T1 and associated
SD-maps were generated using the PSIR MOCO method
[22] and were processed in-line on the scanner, while
R1, ECV, and SD-maps of ECV with co-registration were
processed off-line.In-vivo studies
This study was approved by the local Institutional
Review Boards of the National Heart, Lung, and Blood
Institute and Suburban Hospital, and all subjects gave
written informed consent to participate. Hematocrit
used in calculation of ECV was measured from a venous
blood sample drawn just prior to the CMR study. T1-
maps were typically acquired at least 15 min following
administration of Gd contrast (0.15 mmol/kg) (Gadavist,
Bayer Healthcare). In-vivo data was acquired to (1) meas-
ure typical myocardial SNR, (2) to demonstrate the value
of SD maps in assessing the statistical significance of sub-
tle changes in T1, and (3) to illustrate the application to
measurement of ECV mapping.T1 vs T1 (left column) for various image SNRs for 2 sampling
36 trials, and corresponding standard deviations for R1 = 1/T1
Figure 4 Histogram of T1 errors for case of T1 = 1000 ms, SNR = 30 illustrating the difference between iteratively re-weighted robust
fitting in the presence of outliers.
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The SNR in the myocardium was measured in-vivo in
n = 20 subjects prior to contrast in order to derive typ-
ical values of SNR used in the analysis. Images were
reconstructed with scale in SNR units [29] and values
were measured in manually traced septal and lateral wall
ROIs. Reconstruction in SNR units [29] facilitates SNR
measurement but requires off-line reconstruction from
the raw acquired data. SNR maps were calculated from
the signal intensities of the longest inversion time image
which has achieved steady state. The MOLLI imaging
protocol used for SNR measurement was modified to
acquire 12 heartbeats to ensure complete recovery
was achieved. The sampling for this protocol was
12(1)1, i.e, images acquired for 12 heartbeats on the
first inversion, followed by 1 recovery beat, and
acquisition of 1 additional heartbeat on the second
inversion.Results
SNR measurements
Myocardial SNR with the MOLLI protocol was mea-
sured in 20 subjects using a voxel size of 1.4 × 1.9 × 6
mm3. The SNR in the septum was 43 ± 11 (m ± SD)
and in the lateral wall was 22.8 ± 4.3. The SNR
of the LV blood pool averaged over the full cavity
was 42.7 ± 7.9.Figure 5 T1-map (LEFT) for CuSO4 doped agar gel phantoms for vary
(CENTER), and mean of estimated SD maps for 200 trials using propoMonte Carlo simulation
The measured and calculated estimates for T1 standard
deviation as well as R1 = 1/T1 are graphed (Figure 3) for
a range of T1 and SNR = 20, 30, and 40 which were in
the range of SNRs measured using the specified imaging
protocol. The 5(3)3 sampling strategy is simulated for
T1 in the range 400-1600 ms, and the 4(1)3(1)2 sam-
pling strategy is simulated for T1 in the range 300-500
ms. The estimated SD is within 1 ms of the calculated
SD in all cases, i.e., the estimate is unbiased. The vari-
ability or standard deviation of the SD estimate was
found to be related to the number of inversion time
measurements used in the fit. For the 5(3)3 protocol
with 8 measurements the standard deviation of the SD
estimate was 1/3 of the mean SD value (mean over
ROI), whereas for the 4(1)3(1)2 protocol with 9 mea-
surements, the standard deviation of the SD estimate
was 1/3.3 of the mean SD value. This variability in the
distribution of errors was constant over the range of
T1’s and SNR’s simulated. This variability corresponds to
a single pixel and is reduced by sqrt(N) when averaging
over a ROI with N independent samples which was veri-
fied in the Monte-Carlo simulation by averaging over
blocks of variable length N.
To illustrate the robustness to outliers (Figure 4), the
histogram of T1 measurements for a single protocol
(T1 = 1100 ms, SNR = 20, 5(3)3 sampling) was per-
formed with a single randomly located outlier at 6ing T1 and T2, corresponding SD map calculated from 200 trials
sed method (RIGHT).
Figure 6 Comparison of estimated (proposed method) versus
calculated (200 repeated trials) SD for phantom data shown in
Figure 5.
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both the non-robust (plotted black) and robust (plotted
blue) fitting have similar performance (SD = 30.3 and
31.3 ms, respectively). With a single random outlier the
SD becomes 71.6 ms (plotted red) vs 56 ms for the itera-
tively re-weighted robust fitting (plotted magenta).Phantom measurements
The proposed method of estimating SD was validated in
agar gel phantoms using the method of repeated trials
(Figure 5). The estimated values for SD correlated ex-
tremely well (r = 0.997) with the calculated values across
a range of SD’s for tubes with varying T1, T2 and SNR
(Figure 6).Figure 7 SNR map (left), T1-map (center), and SD map (right). Note th
to decreased SNR resulting from drop off of surface coil sensitivity.In-vivo examples
An example T1-map for a normal subject (Figure 7)
illustrates the variation in T1 estimation error with sur-
face coil intensity variation. The anteroseptal ROI has
SNR = 32.1, T1 = 1012 ms, SD = 25.0 ms, whereas the
lateral wall ROI has lower SNR = 20.9, T1 = 1026 ms,
SD = 41.8 ms (increased). The SNR in the LV blood pool
ROI had T1 = 1580 ms, SNR = 29, and SD = 38 ms.
Example T1-maps illustrate detection of subtle, focal
elevation in T1 in subjects with myocarditis (Figure 8)
and HCM (Figure 9). The subject with myocarditis
(Figure 8) has a focal elevation of the sub-epicardial
region of the lateral wall (1098 ms) corresponding to
103 ms elevation with respect to the septum (995 ms).
The SD of in the lateral wall region is estimated to be
43 ms, i.e., the focal elevation is approximately 2.4 SD
on a pixel-wise basis indicating statistical significance
(P < 0.01) for this individual which has even greater sig-
nificance on a ROI basis (see Discussion).
The subject with HCM (Figure 9) has a focal elevation
of the septal region (1170 ms) corresponding to 84 ms
elevation with respect to the septum (1086 ms). The SD
in the septal region is estimated to be 36 ms, i.e., the
focal elevation is approximately 2.33 SD on a pixel-wise
basis indicating statistical significance (P ≈ 0.01) assum-
ing normal errors. The extension of error maps from T1
to R1 (Figure 10) and ECV (Figure 11) is illustrated for
this subject with HCM. ECV and SD maps (Figure 11)
are calculated from the ΔR1 maps after co-registration
of pre- and post-contrast acquired maps [13] and scaling
for HCT and ΔR1 of the blood pool. The ECV value in a
septal ROI was 34.75% with SD estimated to be 1.0%
and the lateral wall had ECV = 26.2 with SD = 1.2%.
These SD values represent the pixel-wise variation.
Non-rigid motion correction used in these studies is
designed to correct respiratory motion and is not as
effective in correcting cardiac motion due to significant
variation in the RR interval. In these cases, motion
related changes in the signal will lead to increased errore increased T1 standard deviation of T1 at the lateral wall corresponds
Figure 8 Example T1-map and SD map for subject with myocarditis and focal abnormality corresponding to T1 elevation (103 ms)
between lateral wall and septum of 2.4 SD on a pixel-wise basis (lateral wall SD = 43 ms).
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related errors are readily apparent in the SD map
(Figure 12) and may be used to assess the quality of
the T1-map. For the case with more severe cardiac
motion (Figure 12 right) the subject had a regular pat-
tern of premature ventricular contractions (PVCs).Figure 9 Example T1 and SD maps for subject with HCM acquired pre
exhibit focal T1 abnormalities in the septal region corresponding to T1 elev
2.3 SD on a pixel-wise basis (septal SD = 36 ms).Protocol Comparisons
The T1-mapping protocols 5(3)3 and 4(1)3(1)2 used in
this study are compared in Figure 13 with the widely
used original MOLLI protocol 3(3)3(3)5 and the short-
ened MOLLI protocol 5(1)1(1)1 [12] over a range of T1
at an SNR = 25. For the range of T1 values between 300-contrast (TOP) and post-contrast (BOTTOM). Pre-contrast T1 maps
ation of 84 ms relative to the lateral wall representing an elevation of
Figure 10 R1 and SD maps for subject with HCM acquired pre-contrast (TOP) and post-contrast (BOTTOM), corresponding to the
T1-maps shown in Figure 9.
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tration of contrast, the 3(3)3(3)5, 4(1)3(1)2, and 5(1)1(1)
are reasonably similar in performance. For longer
values of T1 where it has been shown that the original
MOLLI becomes heart rate dependent [11] the 5(3)3Figure 11 ECV and SD maps for subject with HCM acquired correspon
blood and HCT values.and shortened MOLLI have been proposed to mitigate
this. The shortened MOLLI reduces the dependence on
heart rate by discarding samples depending on the mea-
sured RR interval. For the case of HR = 60 bpm shown
in Figure 13, the precision of the Sh-MOLLI method isding to the R1-maps shown in Figure 10, calibrated using LV
Figure 12 Example SD maps for illustrating cases with increased error due to uncorrected motion of varying severity. Uncorrected
motion tends to cause local errors in the SD map which are readily recognized due to appearance of anatomical structure. The SD maps serve as
an indication of T1-map quality.
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and is equivalent to 5-1 between 400 and 1000 ms.Discussion
Usefulness of the standard deviation measure
The clinician is frequently faced with the question of
whether a regional variation or a global shift is real or is
a random fluctuation due to noise. The proposed gener-
ation of an error map in meaningful units serves as an
additional metric to aid in measuring statistical significance,
as shown in the examples of Figures 8 and 9. As always, it
is important to use judgement since there are other impor-
tant sources of bias errors and artifacts. For example,
regional variation in off-resonance can cause variation in
apparent T1 which are treated here as bias errors since they
do not increase the random fluctuation. This issue is
important and must be considered in the assessment. The
random component limiting precision is only a single
component to consider, but serves as a performance bound.
The proposed formulation may be used for predicting theFigure 13 Comparison of the precision of various sampling
strategies employed in widely used T1-mapping protocols.precision of T1 and ECV estimates, and permits optimi-
zation and comparison of protocols.Accuracy vs Precision
The issue of accuracy versus precision is an important
subject. Although precision is essential to detecting sub-
tle variations, the ability to detect global shifts in T1 is
also limited by biases unless the normal reference values
are reproducible, known and established. However, one
must exercise caution since there are variable factors
that may influence these “biases” such as off-resonance
and shim, or protocol parameters such as matrix size.
To some extent, the ECV may be less sensitive to accur-
acy in cases where the percentage error is the same for
both myocardium and blood for both pre- and post-
contrast acquisitions; in this case errors could cancel. In
order to realize the full potential of T1 and ECV as
biomarkers, bias errors should be minimized and the
magnitude of any bias variation should be known.SD estimation
Estimates of SD were found to be unbiased when using
the MAD approach for estimating the standard deviation
of fit residuals. The use of iteratively re-weighted fitting
to be robust in the presence of outliers comes at a small
penalty of a few percent in statistical efficiency in the
case for which the data is normally distributed (see dif-
ference between blue and black plots in Figure 4 corre-
sponding to 3% difference in SD). This sacrifice is
deemed to be a small premium to pay for the gain in
protection against outliers.
The largest source of errors in pixel wise T1-mapping
is due to uncompensated heart motion due to variation
in the RR interval, and this may be evident in the SD
map. This increase in estimated SD due to motion error
is apparent from structured appearance of the noise
(Figure 12) and in this instance one must exercise
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Although the formulation has been developed and val-
idated for PSIR reconstructed images, this formulation
may be extended to saturation recovery (SR) methods in
cases where the SNR is reasonably high such that the
noise distribution is sufficiently normal. It is not readily
translated to magnitude IR T1-mapping due to the
approximately Rician noise distribution in magnitude
signal, particularly near the signal nulls. Furthermore, a
frequently used implementation of the MOLLI method
originally described [9,10] that uses the magnitude re-
constructed images is based on a multi-fitting approach
that perform multiple fits based on successfully in-
crementing the unknown time of zero-crossing and
choosing the value with the best fit. This procedure is es-
sentially estimating a 4-th parameter (the zero-crossing)
which degrades the precision for specific values of T1
which have zero-crossings near the inversion times sam-
pled [22].
The error in measuring T1 was found to be well ap-
proximated as a normal distribution, and therefore the
analytic calculation agreed well with the Monte-Carlo
results.
Pixel-wise T1 and SD mapping
T1-measurement on a pixel-wise basis provides the abil-
ity to detect regional heterogeneity and small focal eleva-
tions that might be difficult to identify using ROI based
fitting. It also provides a context for identifying boundar-
ies between blood and myocardium to mitigate partial
volume contamination of ROI regions. Although from a
noise standpoint the precision of fitting to ROIs is better
than the pixel wise fit, the precision of the pixel-wise fits
averaged over an ROI are similarly improved. In the in-
vivo examples shown in Figures 8 and 9, the ROI sizes
in the region of elevated T1 were 48 and 150 pixels,
respectively. The SD of T1 on a ROI basis is improved
by the square root of the number of independent pixels
averaged. The number of independent pixels used to cal-
culate the improvement in SD due to the averaging is
somewhat less due to partial Fourier and parallel im-
aging factors and is estimated to be 40%, corresponding
to 19 and 60 pixel averages, respectively. Thus the pixel-
wise SD in Figure 8 example of 43 ms is approximately
10 ms on a ROI basis, further improving statistical
significance.
SD maps for T1 and ECV may be used to provide confi-
dence for gauging the statistical significance of abnormally
elevated T1 and ECV on a pixel-wise basis, as well as indi-
cating overall quality of the T1-map. Although the SD
maps for current protocols are noisy in appearance, meas-
urement of the SD in typical sized ROIs are dramatically
improved in addition to the improvement in the actual T1values. The ROI size for the septal ROI in the Figure 9 ex-
ample was 150 pixels. Assuming that the actual number of
independent samples was approximately 60 due to inter-
polated reconstruction, the SD estimate of 36 ms had a
variability of 36/3/sqrt(60) = 1.5 ms.
Conclusions
Pixel-wise estimates of T1 mapping errors have been
formulated and validated, and the formulation has been
extended to ECV. The ability to quantify the measurement
error has potential to determine the statistical significance
of subtle abnormalities that arise due to diffuse disease
processes involving fibrosis and/or edema and is useful
both as a confidence metric for overall quality, and in
optimization and comparison of imaging protocols. The
formulation provided may be extended to other paramet-
ric mapping measurements such as T2 or T2*.
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